LIGHT May Improve Immune Checkpoint Blockade Response
Copyright policy )LIGHT May Improve Immune Checkpoint Blockade Response
Abstract A new study suggests that insufficient T-cell infiltration may explain why a majority of patients do not respond to immunotherapy. Combining PD-L1 inhibitors with antibody-guided LIGHT, a protein that recruits tumor-infiltrating lymphocytes, increased antitumor response in mice, and may have the potential to improve patient response rates to immunotherapy.
Tumor Necrosis Factor Ligand Superfamily Member 14, Antineoplastic Agents, Xenograft Model Antitumor Assays, Immunomodulation, Disease Models, Animal, Mice, Lymphocytes, Tumor-Infiltrating, T-Lymphocyte Subsets, Neoplasms, Animals, Humans, Molecular Targeted Therapy
Tumor Necrosis Factor Ligand Superfamily Member 14, Antineoplastic Agents, Xenograft Model Antitumor Assays, Immunomodulation, Disease Models, Animal, Mice, Lymphocytes, Tumor-Infiltrating, T-Lymphocyte Subsets, Neoplasms, Animals, Humans, Molecular Targeted Therapy
selected citations These citations are derived from selected sources.This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).0 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Average influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Average impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Average
Citations provided by BIP!Popularity provided by BIP!